{"schema_version":"secwatch.filing_event.v1","accession":"0001356576-24-000049","form_type":"8-K","ticker":"SUPN","cik":"0001356576","company_name":"SUPERNUS PHARMACEUTICALS, INC.","filed_at":"2024-08-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:12.772324+00:00","generated_at":"2026-05-31T12:11:31.908863+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Supernus Q2 revenues up 24% to $168.3M; Qelbree sales surge 92%; raises FY2024 guidance","bullets":["Total Q2 revenues $168.3M (+24% YoY); Qelbree net sales $59.4M (+92% YoY); GOCOVRI $31.7M (+10% YoY)","Operating income $22.6M; adjusted operating earnings $45.5M, up from $10.0M in Q2 2023","Raising full-year 2024 guidance for total revenues and operating earnings (GAAP and non-GAAP)","Resubmitted NDA for apomorphine infusion device (SPN-830) for Parkinson's motor fluctuations","Phase 2b trial of SPN-820 for TRD expected topline data H1 2025; Phase 2 open-label MDD data by end 2024"],"urls":{"canonical":"https://secwatch.observer/filing/0001356576-24-000049","json":"https://secwatch.observer/filing/0001356576-24-000049.json","markdown":"https://secwatch.observer/filing/0001356576-24-000049.md","text":"https://secwatch.observer/filing/0001356576-24-000049.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1356576/000135657624000049/0001356576-24-000049-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1356576/000135657624000049/supn-20240806.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T12:11:31.908863+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}